National Vaccine
Information Center

Your Health. Your Family. Your Choice.

MedAlerts.org
Search Results

From the 1/14/2022 release of VAERS data:

This is VAERS ID 1148771

Government Disclaimer on use of this data



Case Details

VAERS ID: 1148771 (history)  
Form: Version 2.0  
Age:   
Sex: Male  
Location: Pennsylvania  
Vaccinated:2021-02-25
Onset:2021-03-01
   Days after vaccination:4
Submitted: 0000-00-00
Entered: 2021-03-31
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
COVID19: COVID19 (COVID19 (PFIZER-BIONTECH)) / PFIZER/BIONTECH EN6202 / 1 RA / -

Administered by: Unknown       Purchased by: ?
Symptoms: Asthenia, Blood creatinine, Blood glucose, Full blood count, Guillain-Barre syndrome, Haemoglobin, Metabolic function test, Paraesthesia
SMQs:, Peripheral neuropathy (narrow), Guillain-Barre syndrome (narrow), Demyelination (narrow), Immune-mediated/autoimmune disorders (narrow)

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications: TRULICITY; METOPROLOL [METOPROLOL FUMARATE]; ALOPURINOL; LIPITOR ORIFARM; ASPIRIN [ACETYLSALICYLIC ACID;ASCORBIC ACID]; VITAMIN D3; PROBIOTIC [BIFIDOBACTERIUM LACTIS]
Current Illness:
Preexisting Conditions: Medical History/Concurrent Conditions: Cardiac disorder; Gastrointestinal disorder; Hypertension; Type 2 diabetes mellitus
Allergies:
Diagnostic Lab Data: Test Date: 20210313; Test Name: creatinine; Result Unstructured Data: Test Result:1.19; Comments: slightly elevated; Test Date: 20210313; Test Name: Blood Sugar; Result Unstructured Data: Test Result:140-160; Test Date: 20210313; Test Name: CBC; Result Unstructured Data: Test Result:good; Test Date: 20210313; Test Name: hemoglobin; Result Unstructured Data: Test Result:7.6; Comments: 7.6 out of range; Test Date: 20210313; Test Name: CMP; Result Unstructured Data: Test Result:all good
CDC Split Type: USPFIZER INC2021283872

Write-up: ascending bilateral symmetrical paresthesias in the legs to upper thighs and fingers of both hands; slight weakness; Guillain-Barre Syndrome; This is a spontaneous report from a contactable physician. A male patient of an unspecified age received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: EN6202, expiration date: unknown), via an unspecified route of administration in right arm on 25Feb2021 at 15:30 as single dose for COVID-19 immunization. The patient''s medical history included hypertension, type 2 diabetes, and cardiac issues. Concomitant medication included dulaglutide (TRULICITY); metoprolol fumarate; alopurinol; atorvastatin calcium (LIPITOR ORIFARM); acetylsalicylic acid, ascorbic acid (ASPIRIN [ACETYLSALICYLIC ACID;ASCORBIC ACID]); vitamin d3; bifidobacterium lactis (PROBIOTIC [BIFIDOBACTERIUM LACTIS]), all ongoing for unspecified indication. The patient previously took Flu vaccine on an unspecified date for immunization. In Mar2021 (reported as after several days), the patient developed ascending bilateral symmetrical paresthesias in the legs to upper thighs and fingers of both hands peaking at 7-8 days and now slightly improving but persistent and associated with slight weakness suggesting Guillain-Barre Syndrome. The patient underwent lab tests and procedures which included blood creatinine: 1.19 (slightly elevated), blood sugar 140-160, complete blood count (CBC): good, haemoglobin: 7.6 (out of range), metabolic function test: all good on 13Mar2021. The patient did not received treatment for the events. The outcome of the events was recovering.; Sender''s Comments: Based on the current available information and the plausible drug-event temporal association, a possible contributory role of the suspect product BNT162B2 to the development of event Guillain-Barre syndrome cannot be excluded. The case will be reassessed if additional information becomes available. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees and Investigators, as appropriate.


New Search

Link To This Search Result:

https://medalerts.org/vaersdb/findfield.php?IDNUMBER=1148771


Copyright © 2022 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166